skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Impact of dronedarone in atrial fibrillation and flutter on stroke reduction

Review

(3498) Views  (1036) Full article downloads

Authors: Christine Benn Christiansen, Christian Torp-Pedersen, Lars Køber

Published Date March 2010 Volume 2010:5 Pages 63 - 69
DOI: http://dx.doi.org/10.2147/CIA.S8883

Christine Benn Christiansen1, Christian Torp-Pedersen1, Lars Køber2

1Department of Cardiology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; 2Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Background: Dronedarone has been developed for treatment of atrial fibrillation (AF) or atrial flutter (AFL). It is an amiodarone analogue but noniodinized and without the same adverse effects as amiodarone.

Objective and methods: This is a review of 7 studies (DAFNE, ADONIS, EURIDIS, ATHENA, ANDROMEDA, ERATO and DIONYSOS) on dronedarone focusing on efficacy, safety and prevention of stroke. There was a dose-finding study (DAFNE), 3 studies focusing on maintenance of sinus rhythm (ADONIS, EURIDIS and DIONYSOS), 1 study focusing on rate control (ERATO) and 2 studies investigating mortality and morbidity (ANDROMEDA and ATHENA).

Results: The target dose for dronedarone was established in the DAFNE study to be 400 mg twice daily. Both EURIDIS and ADONIS studies demonstrated that dronedarone was superior to placebo for maintaining sinus rhythm. However, DIONYSOS found that dronedarone is less efficient at maintaining sinus rhythm than amiodarone. ERATO concluded that dronedarone reduces ventricular rate in patients with chronic AF. The ANDROMEDA study in patients with severe heart failure was discontinued because of increased mortality in dronedarone group. Dronedarone reduced cardiovascular hospitalizations and mortality in patients with AF or AFL in the ATHENA trial. Secondly, according to a post hoc analysis a significant reduction in stroke was observed (annual rate 1.2% on dronedarone vs 1.8% on placebo, respectively [hazard ratio 0.66, confidence interval 0.46 to 0.96, P = 0.027]). In total, 54 cases of stroke occurred in 3439 patients (crude rate 1.6%) receiving dronedarone compared to 76 strokes in 3048 patients on placebo (crude rate 2.5%), respectively.

Conclusion: Dronedarone can be used for maintenance of sinus rhythm and can reduce stroke in patients with AF who receive usual care, which includes antithrombotic therapy and heart rate control.

Keywords: atrial fibrillation, stroke, dronedarone








Readers of this article also read:

Can cellulite be treated with low-energy extracorporeal shock wave therapy?
Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Dronedarone for atrial fibrillation: a new therapeutic agent
Management of hyperuricemia in gout: focus on febuxostat
Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene
Omega-3 fatty acids: potential role in the management of early Alzheimer’s disease
Antithrombotic therapy in very elderly patients with atrial fibrillation: Is it enough to assess thromboembolic risk?
Advantages of dietary, exercise-related, and therapeutic interventions to prevent and treat sarcopenia in adult patients: an update
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy